Found 8 hits Enz. Inhib. hit(s) with Target = 'Tyrosine-protein kinase BTK' and Ligand = 'BDBM230099' Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230099
(US10106559, Example 24 | US10435415, Example 24 | ...)Show SMILES Cc1c(cccc1-n1c(=O)ccn(-c2ccc(F)cc2)c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.42,-.77,;.08,-1.54,;-1.25,-.77,;-2.58,-1.54,;-2.58,-3.08,;-1.25,-3.85,;.08,-3.08,;1.42,-3.85,;1.42,-5.39,;.08,-6.16,;2.75,-6.16,;4.09,-5.39,;4.09,-3.85,;5.42,-3.08,;6.75,-3.85,;8.09,-3.08,;8.09,-1.54,;9.42,-.77,;6.75,-.77,;5.42,-1.54,;2.75,-3.08,;2.75,-1.54,;-1.25,.77,;.08,1.54,;1.42,.77,;.08,3.08,;-1.25,3.85,;-1.25,5.39,;.08,6.16,;-2.58,6.16,;-2.58,3.08,;-4.05,3.56,;-4.95,2.31,;-6.48,2.15,;-7.11,.74,;-6.21,-.5,;-4.67,-.34,;-4.05,1.06,;-2.58,1.54,;-8.65,.74,;-9.42,-.59,;-7.88,-.59,;-9.42,2.08,)| Show InChI InChI=1S/C33H26ClFN4O4/c1-17-21(5-4-6-26(17)39-27(40)13-14-38(32(39)42)20-10-8-19(35)9-11-20)28-24(34)16-23(31(36)41)30-29(28)22-12-7-18(33(2,3)43)15-25(22)37-30/h4-16,37,43H,1-3H3,(H2,36,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.330 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10106559 (2018)
BindingDB Entry DOI: 10.7270/Q2SF2Z7Q |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230099
(US10106559, Example 24 | US10435415, Example 24 | ...)Show SMILES Cc1c(cccc1-n1c(=O)ccn(-c2ccc(F)cc2)c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.42,-.77,;.08,-1.54,;-1.25,-.77,;-2.58,-1.54,;-2.58,-3.08,;-1.25,-3.85,;.08,-3.08,;1.42,-3.85,;1.42,-5.39,;.08,-6.16,;2.75,-6.16,;4.09,-5.39,;4.09,-3.85,;5.42,-3.08,;6.75,-3.85,;8.09,-3.08,;8.09,-1.54,;9.42,-.77,;6.75,-.77,;5.42,-1.54,;2.75,-3.08,;2.75,-1.54,;-1.25,.77,;.08,1.54,;1.42,.77,;.08,3.08,;-1.25,3.85,;-1.25,5.39,;.08,6.16,;-2.58,6.16,;-2.58,3.08,;-4.05,3.56,;-4.95,2.31,;-6.48,2.15,;-7.11,.74,;-6.21,-.5,;-4.67,-.34,;-4.05,1.06,;-2.58,1.54,;-8.65,.74,;-9.42,-.59,;-7.88,-.59,;-9.42,2.08,)| Show InChI InChI=1S/C33H26ClFN4O4/c1-17-21(5-4-6-26(17)39-27(40)13-14-38(32(39)42)20-10-8-19(35)9-11-20)28-24(34)16-23(31(36)41)30-29(28)22-12-7-18(33(2,3)43)15-25(22)37-30/h4-16,37,43H,1-3H3,(H2,36,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.330 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9850258 (2017)
BindingDB Entry DOI: 10.7270/Q27S7R2C |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230099
(US10106559, Example 24 | US10435415, Example 24 | ...)Show SMILES Cc1c(cccc1-n1c(=O)ccn(-c2ccc(F)cc2)c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.42,-.77,;.08,-1.54,;-1.25,-.77,;-2.58,-1.54,;-2.58,-3.08,;-1.25,-3.85,;.08,-3.08,;1.42,-3.85,;1.42,-5.39,;.08,-6.16,;2.75,-6.16,;4.09,-5.39,;4.09,-3.85,;5.42,-3.08,;6.75,-3.85,;8.09,-3.08,;8.09,-1.54,;9.42,-.77,;6.75,-.77,;5.42,-1.54,;2.75,-3.08,;2.75,-1.54,;-1.25,.77,;.08,1.54,;1.42,.77,;.08,3.08,;-1.25,3.85,;-1.25,5.39,;.08,6.16,;-2.58,6.16,;-2.58,3.08,;-4.05,3.56,;-4.95,2.31,;-6.48,2.15,;-7.11,.74,;-6.21,-.5,;-4.67,-.34,;-4.05,1.06,;-2.58,1.54,;-8.65,.74,;-9.42,-.59,;-7.88,-.59,;-9.42,2.08,)| Show InChI InChI=1S/C33H26ClFN4O4/c1-17-21(5-4-6-26(17)39-27(40)13-14-38(32(39)42)20-10-8-19(35)9-11-20)28-24(34)16-23(31(36)41)30-29(28)22-12-7-18(33(2,3)43)15-25(22)37-30/h4-16,37,43H,1-3H3,(H2,36,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.330 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10435415 (2019)
BindingDB Entry DOI: 10.7270/Q2C53P6V |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230099
(US10106559, Example 24 | US10435415, Example 24 | ...)Show SMILES Cc1c(cccc1-n1c(=O)ccn(-c2ccc(F)cc2)c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.42,-.77,;.08,-1.54,;-1.25,-.77,;-2.58,-1.54,;-2.58,-3.08,;-1.25,-3.85,;.08,-3.08,;1.42,-3.85,;1.42,-5.39,;.08,-6.16,;2.75,-6.16,;4.09,-5.39,;4.09,-3.85,;5.42,-3.08,;6.75,-3.85,;8.09,-3.08,;8.09,-1.54,;9.42,-.77,;6.75,-.77,;5.42,-1.54,;2.75,-3.08,;2.75,-1.54,;-1.25,.77,;.08,1.54,;1.42,.77,;.08,3.08,;-1.25,3.85,;-1.25,5.39,;.08,6.16,;-2.58,6.16,;-2.58,3.08,;-4.05,3.56,;-4.95,2.31,;-6.48,2.15,;-7.11,.74,;-6.21,-.5,;-4.67,-.34,;-4.05,1.06,;-2.58,1.54,;-8.65,.74,;-9.42,-.59,;-7.88,-.59,;-9.42,2.08,)| Show InChI InChI=1S/C33H26ClFN4O4/c1-17-21(5-4-6-26(17)39-27(40)13-14-38(32(39)42)20-10-8-19(35)9-11-20)28-24(34)16-23(31(36)41)30-29(28)22-12-7-18(33(2,3)43)15-25(22)37-30/h4-16,37,43H,1-3H3,(H2,36,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.330 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230099
(US10106559, Example 24 | US10435415, Example 24 | ...)Show SMILES Cc1c(cccc1-n1c(=O)ccn(-c2ccc(F)cc2)c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.42,-.77,;.08,-1.54,;-1.25,-.77,;-2.58,-1.54,;-2.58,-3.08,;-1.25,-3.85,;.08,-3.08,;1.42,-3.85,;1.42,-5.39,;.08,-6.16,;2.75,-6.16,;4.09,-5.39,;4.09,-3.85,;5.42,-3.08,;6.75,-3.85,;8.09,-3.08,;8.09,-1.54,;9.42,-.77,;6.75,-.77,;5.42,-1.54,;2.75,-3.08,;2.75,-1.54,;-1.25,.77,;.08,1.54,;1.42,.77,;.08,3.08,;-1.25,3.85,;-1.25,5.39,;.08,6.16,;-2.58,6.16,;-2.58,3.08,;-4.05,3.56,;-4.95,2.31,;-6.48,2.15,;-7.11,.74,;-6.21,-.5,;-4.67,-.34,;-4.05,1.06,;-2.58,1.54,;-8.65,.74,;-9.42,-.59,;-7.88,-.59,;-9.42,2.08,)| Show InChI InChI=1S/C33H26ClFN4O4/c1-17-21(5-4-6-26(17)39-27(40)13-14-38(32(39)42)20-10-8-19(35)9-11-20)28-24(34)16-23(31(36)41)30-29(28)22-12-7-18(33(2,3)43)15-25(22)37-30/h4-16,37,43H,1-3H3,(H2,36,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.440 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10435415 (2019)
BindingDB Entry DOI: 10.7270/Q2C53P6V |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230099
(US10106559, Example 24 | US10435415, Example 24 | ...)Show SMILES Cc1c(cccc1-n1c(=O)ccn(-c2ccc(F)cc2)c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.42,-.77,;.08,-1.54,;-1.25,-.77,;-2.58,-1.54,;-2.58,-3.08,;-1.25,-3.85,;.08,-3.08,;1.42,-3.85,;1.42,-5.39,;.08,-6.16,;2.75,-6.16,;4.09,-5.39,;4.09,-3.85,;5.42,-3.08,;6.75,-3.85,;8.09,-3.08,;8.09,-1.54,;9.42,-.77,;6.75,-.77,;5.42,-1.54,;2.75,-3.08,;2.75,-1.54,;-1.25,.77,;.08,1.54,;1.42,.77,;.08,3.08,;-1.25,3.85,;-1.25,5.39,;.08,6.16,;-2.58,6.16,;-2.58,3.08,;-4.05,3.56,;-4.95,2.31,;-6.48,2.15,;-7.11,.74,;-6.21,-.5,;-4.67,-.34,;-4.05,1.06,;-2.58,1.54,;-8.65,.74,;-9.42,-.59,;-7.88,-.59,;-9.42,2.08,)| Show InChI InChI=1S/C33H26ClFN4O4/c1-17-21(5-4-6-26(17)39-27(40)13-14-38(32(39)42)20-10-8-19(35)9-11-20)28-24(34)16-23(31(36)41)30-29(28)22-12-7-18(33(2,3)43)15-25(22)37-30/h4-16,37,43H,1-3H3,(H2,36,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.440 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10106559 (2018)
BindingDB Entry DOI: 10.7270/Q2SF2Z7Q |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230099
(US10106559, Example 24 | US10435415, Example 24 | ...)Show SMILES Cc1c(cccc1-n1c(=O)ccn(-c2ccc(F)cc2)c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.42,-.77,;.08,-1.54,;-1.25,-.77,;-2.58,-1.54,;-2.58,-3.08,;-1.25,-3.85,;.08,-3.08,;1.42,-3.85,;1.42,-5.39,;.08,-6.16,;2.75,-6.16,;4.09,-5.39,;4.09,-3.85,;5.42,-3.08,;6.75,-3.85,;8.09,-3.08,;8.09,-1.54,;9.42,-.77,;6.75,-.77,;5.42,-1.54,;2.75,-3.08,;2.75,-1.54,;-1.25,.77,;.08,1.54,;1.42,.77,;.08,3.08,;-1.25,3.85,;-1.25,5.39,;.08,6.16,;-2.58,6.16,;-2.58,3.08,;-4.05,3.56,;-4.95,2.31,;-6.48,2.15,;-7.11,.74,;-6.21,-.5,;-4.67,-.34,;-4.05,1.06,;-2.58,1.54,;-8.65,.74,;-9.42,-.59,;-7.88,-.59,;-9.42,2.08,)| Show InChI InChI=1S/C33H26ClFN4O4/c1-17-21(5-4-6-26(17)39-27(40)13-14-38(32(39)42)20-10-8-19(35)9-11-20)28-24(34)16-23(31(36)41)30-29(28)22-12-7-18(33(2,3)43)15-25(22)37-30/h4-16,37,43H,1-3H3,(H2,36,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.440 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9850258 (2017)
BindingDB Entry DOI: 10.7270/Q27S7R2C |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230099
(US10106559, Example 24 | US10435415, Example 24 | ...)Show SMILES Cc1c(cccc1-n1c(=O)ccn(-c2ccc(F)cc2)c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.42,-.77,;.08,-1.54,;-1.25,-.77,;-2.58,-1.54,;-2.58,-3.08,;-1.25,-3.85,;.08,-3.08,;1.42,-3.85,;1.42,-5.39,;.08,-6.16,;2.75,-6.16,;4.09,-5.39,;4.09,-3.85,;5.42,-3.08,;6.75,-3.85,;8.09,-3.08,;8.09,-1.54,;9.42,-.77,;6.75,-.77,;5.42,-1.54,;2.75,-3.08,;2.75,-1.54,;-1.25,.77,;.08,1.54,;1.42,.77,;.08,3.08,;-1.25,3.85,;-1.25,5.39,;.08,6.16,;-2.58,6.16,;-2.58,3.08,;-4.05,3.56,;-4.95,2.31,;-6.48,2.15,;-7.11,.74,;-6.21,-.5,;-4.67,-.34,;-4.05,1.06,;-2.58,1.54,;-8.65,.74,;-9.42,-.59,;-7.88,-.59,;-9.42,2.08,)| Show InChI InChI=1S/C33H26ClFN4O4/c1-17-21(5-4-6-26(17)39-27(40)13-14-38(32(39)42)20-10-8-19(35)9-11-20)28-24(34)16-23(31(36)41)30-29(28)22-12-7-18(33(2,3)43)15-25(22)37-30/h4-16,37,43H,1-3H3,(H2,36,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.440 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Search and Browse
